Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Adolescents With Chronic Spontaneous Urticaria
NCT05677451Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of remibrutinib in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Jul 2023; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05677451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677451.